Loading clinical trials...
Loading clinical trials...
Treating Primary Progressive Aphasia (PPA) and Elucidating Neurodegeneration in the Language Network Using Transcranial Direct Current Stimulation (tDCS)
This is a double-blind, sham-controlled, crossover study in which subjects with the non-fluent/agrammatic and logopenic variants of primary progressive aphasia (naPPA and lvPPA, respectively) will undergo language testing and structural and functional brain imaging before and after receiving 10 semi-consecutive daily sessions of real or sham high-definition transcranial direct current stimulation (HD-tDCS) paired with modified constraint-induced language therapy (mCILT). Language testing and brain imaging will be repeated immediately after completion of and 3 months following completion of treatment. The 3-month follow-up will be the primary endpoint. The investigators will examine changes in language performance induced by HD-tDCS + mCILT compared to sham HD-tDCS + mCILT. The investigators will also use network science to analyze brain imaging (fMRI) data to identify network properties associated with baseline PPA severity and tDCS-induced changes in performance. This study will combine knowledge gained from our behavioral, imaging, and network data in order to determine the relative degrees to which these properties predict whether persons with PPA will respond to intervention.
The central framework for the project is a double-blind, sham-controlled, crossover study in which subjects with the non-fluent/agrammatic and logopenic variants of primary progressive aphasia (naPPA and lvPPA, respectively) will undergo language testing and structural and functional brain imaging before and after receiving 10 semi-consecutive daily sessions of real or sham high definition transcranial direct current stimulation (HD-tDCS) paired with modified constraint-induced language therapy (mCILT). Language testing and brain imaging will be repeated immediately after completion of and 3 months following completion of treatment. Subjects with naPPA and lvPPA will be randomized to one of two study arms: HD-tDCS+mCILT or sham stimulation+mCILT paired with pre- and post-stimulation imaging and behavioral measures. Equal numbers of subjects with naPPA and lvPPA will be randomized to the HD-tDCS + mCILT and sham + mCILT study arms. The study is double-blinded, in that neither the subject nor the study personnel administering HD-tDCS or sham stimulation will know which arm of the study the subject has been randomized into. Study coordinators will administer HD-tDCS by entering a pre-determined code that has been programmed into the device by another member of the study team. Data will be digitally audio-recorded and analyzed off-line, such that study team members performing data coding and analysis will likewise be blinded to the treatment condition of each subject. Subject participation in this protocol will occur during 27 planned visits that will span approximately 8 months. The events of the study visits are described below: VISIT 1: a Informed consent and screening b. Baseline language assessment #1 c. Baseline MRI scanning VISIT 2: Baseline language assessment #2 VISITS 3-11: HD-tDCS+mCILT OR sham stimulation+mCILT, depending on the study arm to which they had been randomized. VISIT 12: 1. Final session of HD-tDCS+mCILT or sham stimulation+mCILT 2. Follow-up language assessment 3. Follow-up MRI VISIT 13: 6-Week follow-up language assessment VISIT 14: 1. 12-week follow-up language assessment 2. 12-week follow-up MRI \*\*CROSSOVER\*\* VISIT 15: Crossover baseline language assessment #2 VISITS 16-24: HD-tDCS+mCILT or sham stimulation+mCILT VISIT 25: 1. 10th session of HD-tDCS+mCILT or sham stimulation+mCILT 2. Follow-up language assessment 3. Follow-up MRI VISIT 26: 6 Week follow-up language assessment: VISIT 27: 1. 12-week follow-up language assessment 2. 12-week follow-up MRI
Age
45 - 80 years
Sex
ALL
Healthy Volunteers
No
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
August 17, 2020
Primary Completion Date
June 30, 2025
Completion Date
June 30, 2025
Last Updated
October 15, 2025
76
ACTUAL participants
high-definition transcranial direct current stimulation
DEVICE
modified constraint-induced language therapy
BEHAVIORAL
Lead Sponsor
University of Pennsylvania
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05741853